Abstract
Purpose :
We performed a retrospective, observational clinical studyto study changes in amount of metamorphopsia after anti-VEGF therapy for macular edema (ME) in branch retinal vein occlusion (BRVO).
Methods :
This study enrolled 29 eyes of 29 patients with ME secondary to BRVO. Those patients were treated with intravitreal injections of anti-VEGF agents using a TAE regimen for at least 18 months at Kyushu University Hospital. We evaluated log MAR visual acuity, central macular thickness(CMT), ME recurrence and amount of metamorphopsia that was quantified by M-CHARTS.
Results :
Log MAR visual acuity and CMT significantly improved from 0.35±0.29 and 468±106μm at baseline to 0.06±0.18 and 289±82μm at 18 months (P<0.0001). The average vertical M-CHARTS score significantly decreased from 0.75±0.73 at baseline to 0.59±0.52 and 0.54±0.45 at 1 and 6 months and the horizontal M-CHARTS score significantly decreased from 0.50±0.45 at baseline to 0.35±0.37 at 6 months (p<0.05). However, neither vertical nor horizontal M-CHARTS significantly changed at 18 months (vertical: 0.56±0.58(P=0.10) and horizontal: 0.37±0.44(P=0.12)).ME recurrence occurred in 22 eyes during the follow-up period (75.9%). The number of ME recurrence was significantly smaller in the eyes with maintained or improved vertical M-CHARTS than those with worsened vertical M-CHARTS at 18 months (p<0.05).
Conclusions :
Anti-VEGF therapy using TAE regimen may not improve metamorphopsia in BRVO-ME after long-term follow-up.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.